KR20020074619A - Ultraviolet B's sunlight lamp for osteoporosis treatment and the composition for it's shade - Google Patents

Abstract

PURPOSE: Provided are a medium wave ultraviolet lamp for osteoporosis therapy which increases the generation of vitamin D3 in serum and bone density, and the composition for use in the lamp. CONSTITUTION: The lamp comprises a mixed powder(which is a composition for the lamp) containing SrCO3(strontium carbonate), MgO(magnesium oxide), H3BO3(hydrogen borate), PbO2(zinc oxide), and CeO2(cerium oxide) and Gd2O3(gadolinium oxide), as an activator, admixed into 80-95 wt% of Ca3(PO4)2(calcium phosphate) as a fluorescent component, which is fired at high temperature; and a lamp pipe formed of sodium glass. The contents of Ca3(PO4)2, SrCO3, MgO, H3BO3, PbO2, CeO2, and Gd2O3 are 80-95 wt%, 3-18 wt%, 0.05-15.05 wt%, 1-16 wt%, 0.4-15.4 wt%, 0.30-15.30 wt% and 0.25-15.25 wt%, respectively.

Description

Ultraviolet B's sunlight lamp for osteoporosis treatment and the composition for it's shade}

TECHNICAL FIELD The present invention relates to a daylight lamp that emits medium-wave ultraviolet radiation suitable for the prevention and treatment of osteoporosis, and a composition for halving thereof.

Medium-wave ultraviolet rays refer to a region of wavelength 280-320 nm, commonly known as ultraviolet B (abbreviated UVB or UV-B). These wavelengths are at the lower edge of the ultraviolet absorbing group of the ozone layer. Ultraviolet B wavelengths from the sun have been known to be biologically harmful since the 70s, except they are effective against rickets caused by lack of vitamin D. Deficiency of vitamin D or its disruptive processes all lead to disturbances in calcium phosphate metabolism in the body, leading to rickets, chondrosis, and osteoporosis. Recently, it has been found that osteoporosis, which affects more than 60% of older people, can be treated by promoting bone production by vitamin D ₃ .

Meanwhile, methods for artificially preventing and treating rickets in children using medium-wave ultraviolet daylights (aka health daylights) have been known. Reduced to ferrous oxide), and the equal parts were mixed with SrCO ₃ , MgO, H ₃ BO ₃ , Gd ₂ O ₃ , PbO ₂ at a constant ratio, baked, cooled, and sieved. In particular, Ca (PO ₄ ) ₂ (calcium phosphate) is contained in about 50% by weight, and the remaining components to add up to 50% by weight, which is currently produced and sold by various companies in Korea for the treatment and prevention of osteoporosis Not only was it used, but the effect was weak.

In addition, the medium-wave infrared daylight obtained by the above-described method often has a problem that the wavelength region does not coincide with time, its transmission amount is relatively small, and the conditions for safety procedures are difficult. In addition, there was a light damage phenomenon such as skin pigmentation or conjunctiva of the eye after the daylight, and serum Ca ²⁺ and vitamin D ₃ contents were relatively low.

Accordingly, an object of the present invention is to improve the material (substance) of the isotubes and equal parts so that the wavelength of 280-320nm is generated stably, and the light intensity of the medium-wave ultraviolet region is strengthened so that the vitamin D of serum without side effects when it is applied to the skin _It is to provide medium-wave ultraviolet rays for osteoporosis therapies that produce conversion of ₃ and increase bone density.

Another object of the present invention is to provide a composition for equal fractionation in daylighting lamp of the above object.

The technical issue of the present invention lies in the components of equal parts as a substance and the fluorine content in them, and also relates to the selective application of iso-glass glass materials.

The present invention is described in more detail as follows.

The medium-wave ultraviolet ray daylight for osteoporosis therapy of the present invention is SrCO ₃ (stromium carbonate), MgO (magnesium oxide), H in 80 to 95% by weight of Ca ₃ (PO ₄ ) ₂ (calcium phosphate), which is a fluorescent component in equal parts. ₃ BO ₃ (hydrogen borate), PbO ₂ (lead oxide), and CeO ₂ (cerium oxide) and Gd ₂ O ₃ (gadolinium oxide) mixed powder of high-temperature firing containing the active agent, the isotonic is made of sodium glass It is characterized by the configuration.

In addition, the composition for equal distribution is 80 to 95% by weight of Ca ₃ (PO ₄ ) ₂ (calcium phosphate), which is a fluorescent powder, 3 to 18% by weight of SrCO ₃ (stromium carbonate), 0.05 to 15.05% by weight of MgO (magnesium oxide), 1 to 16 weight percent H ₃ BO ₃ (hydrogen borate), 0.4 to 15.4 weight percent PbO ₂ (lead oxide), and 0.30 to 15.30 weight percent CeO ₂ (cerium oxide) and 0.25 to 15.25 Gd ₂ O ₃ (gadolinium oxide) It is a mixed powder of high temperature firing containing the weight% as an activator, and the isotubes are characterized by selective application of sodium glass.

The ratio of the components to obtain the most suitable conditions is 91.46% by weight Ca ₃ (PO ₄ ) ₂ (calcium phosphate), 4.35% by weight SrCO ₃ (stromium carbonate), 0.12% by weight MgO (magnesium oxide), H ₃ BO ₃ ( Hydrogen borate), 2.90 wt%, PbO ₂ (lead oxide) 0.50 wt%, CeO ₂ (cerium oxide) 0.39 wt%, and Gd ₂ O ₃ (gadolinium oxide) 0.28 wt%.

When the above components are used, the amount of calcium phosphate used is at least 30% higher than before, and although the mechanism of action is not clearly identified, nontoxic rare earth ions such as CeO ₂ and Gd ₂ O ₃ are activated to remove toxic thallium ions. do. In addition, the white calcium phosphate is at least 80% by weight, and its content is higher than that of the prior art, and a small amount of the components containing the active agent is multiplied at the ratio of biomass, so that the light is soft and the illumination is enhanced, and the patient is Do not feel uncomfortable for a long time even if you work below. In addition, thermal stability is improved and vapor deposition in the isotubes is facilitated. The above equal can emit medium-wave ultraviolet light under the 254nm ultraviolet light burst, and the maximum rise is around 303nm.

The production process of equal parts is prepared by weighing and mixing the pure chemical raw materials of Ca ₃ (PO ₄ ) ₂ , SrCO ₃ , MgO, H ₃ BO ₃ , PbO ₂ , CeO ₂ , Gd ₂ O _{3 in} the above-mentioned ratio, Bake at 800 ~ 1000 ℃ by solid phase method. Continue roasting for 1 to 2 hours, then cool and sift to obtain the finished portion.

When the isophore is made of sodium glass, wavelengths of 280 nm or less are not transmitted, and at least 80% of medium-wave ultraviolet rays larger than or equal to the wavelength of 300 nm are transmitted. Lamp is the sodium glass among the glass that can be used for the current lamp. In this class of isotubes, it is suitable to realize the result to be obtained in the present invention when such equal parts are deposited.

The medium-wave ultraviolet ray lamp obtained by depositing equal parts in the lamp tube belongs to a vapor compression type discharge lamp, and has a very low cold and cold feeling. When the lamp is turned on, during the preheating of the filament, the metal dehydrogenide of the filament causes thermal transfer to be fired, and then generates and discharges low pressure steam in the lamp to emit light. The emission spectrum is a continuous spectrum of 280 to 700 nm. The isophores begin to transmit light at a wavelength of 280 nm and no light shorter than this wavelength. Thereafter, 80% is maintained in the vicinity of the wavelength of 300 nm. The amount of medium-wave ultraviolet intensity emitted by daylight is 1/8 MED (minimum red spot).

When the sun shines on the skin, it converts the subcutaneous 7-dehydrogen cholesterol into vitamin D ₃ and thus promotes the body's calcium and phosphorus metabolism.

-2H ultraviolet

Cholesterol-→ 7-Dehydrogen Cholesterol-→ Vitamin D ₃

Blood skin

Example 1

91.46% Ca ₃ (PO ₄ ) ₂ , 4.35% SrCO ₃ , 0.12% MgO, 2.90% H ₃ BO ₃ , 0.50% PbO ₂ , 0.39% CeO ₂ , 0.28% Gd ₂ O ₃ After weighing as precisely as possible, the mixture was evenly mixed and calcined at 950 ° C. for 1 hour by a solid phase method to prepare an equivalent, and a daylight lamp was manufactured by a conventional method using sodium glass as the lamp.

Comparative Example 1

50% by weight of Ca ₃ (PO ₄ ) ₂ , 25% by weight of SrCO ₃ , 15% by weight of MgO, 5% by weight of H ₃ BO _3, 5% by weight of PbO ₂ , accurately weighed, mixed evenly, and solidified by 950 The mixture was calcined at 1 ° C. for 1 hour to prepare equal parts, and a daylight lamp was manufactured by a conventional method using ordinary UV-transmitting glass as a lamp tube.

Clinical Experiment 1

Patients with osteoporosis at an average age of 63.3 ± 10.8 years (71 males, 42 females) were treated for one month, except for those who did not significantly affect bone calcium metabolism. The daylight lamps prepared in Example 1 and Comparative Example 1 were placed at a distance of about 2.2 m from the ground and dropped about 1.5 m from the face and hands of the person lying down. The illuminance is 6 kW / cm 2, and the amount used for 2-4 hours is 0.72-0.96 kW / cm 2. During the treatment, the drug that affects the bone calcium metabolism is prohibited, and during the treatment and after the treatment, red blood cells, hemoglobin, serum Ca ²⁺ , P ⁼ , vitamin D ₃ content (measurement: fluorescence test), bone density of the radial and vertebrae Comparative observation was made.

As a result of treatment, the daylight of Example 1 had no skin pigmentation or conjunctival hyperemia and no other side effects. All of the subjects' subjective assessments of feeling were positive (84.07% responded well). Serum Ca ²⁺ , P ⁼ levels, vitamin D ₃ content, and bone mineral density increased after treatment, with no significant changes in erythrocytes and hemoglobin. However, the daylight of Comparative Example 1 had skin pigmentation or conjunctival hyperemia and other side effects. The patient's subjective evaluation of feeling was almost negative (63.52% was a bad response). Serum Ca ²⁺ , P ⁼ level, vitamin D ₃ content, and BMD showed little increase after treatment, and red blood cell and hemoglobin changes. Was not.

Clinical Experiment 2

Patients with osteoporosis (45 males, 8 females) with an average age of 67.4 ± 7.1 years were treated for one month, except for the owners of the disease that did not significantly affect bone calcium metabolism. The daylight lamps prepared in Example 1 and Comparative Example 1 were placed at a distance of about 2.2 m from the ground and dropped about 1.5 m from the face and hands of the person lying down. The illuminance is 6 kW / cm 2, and the amount used for 2-4 hours is 0.72-0.96 kW / cm 2. During the treatment, the administration of drugs affecting bone calcium metabolism was prohibited, and red blood cells, hemoglobin, serum Ca ²⁺ , P ⁼ and vitamin D ₃ contents (measurement: fluorescence detection) were compared during and after treatment.

As a result of treatment, the daylight of Example 1 had no skin pigmentation or conjunctival hyperemia and no other side effects. All of the subject's subjective assessments of feeling were positive (94% said good). Serum Ca ²⁺ , P ⁼ levels and vitamin D ₃ content increased after treatment, with no significant changes in erythrocytes and hemoglobin. However, the daylight of Comparative Example 1 had skin pigmentation or conjunctival hyperemia and other side effects. The patient's subjective evaluation of feeling was almost negative (52.01% was a bad response). Serum Ca ²⁺ , P ⁼ level, vitamin D ₃ content, and BMD showed little increase after treatment, and red blood cell and hemoglobin changes. Was not.

Clinical Experiment 3

Patients with osteoporosis at an average age of 64.3 ± 4.2 years (13 males and 17 females) were treated for one month, except for those who did not significantly affect bone calcium metabolism. The daylight lamps prepared in Example 1 and Comparative Example 1 were placed at a distance of about 2.2 m from the ground and dropped about 1.5 m from the face and hands of the person lying down. The illuminance is 6 kW / cm 2, and the amount used for 2-4 hours is 0.72-0.96 kW / cm 2. During the treatment, the administration of drugs affecting bone calcium metabolism was prohibited, and the bone mineral density of erythrocytes, hemoglobin, serum Ca ²⁺ , P ⁼ , radial and vertebrae were compared during and after treatment.

As a result of treatment, the daylight of Example 1 had no skin pigmentation or conjunctival hyperemia and no other side effects. In subjective evaluation of feeling, all were positive (70% was good) and bone density increased but there was no significant change in serum Ca ²⁺ , P ⁼ , red blood cells, and hemoglobin. However, the daylight of Comparative Example 1 had skin pigmentation or conjunctival hyperemia and other side effects. The patient's subjective evaluation of feeling was almost negative (88% were bad) and there was little change in serum Ca ²⁺ , P ⁼ levels, vitamin D ₃ content, bone density, and red blood cells and hemoglobin.

Measurement results before and after treatment for red blood cells and hemoglobin of the above clinical trials 1 to 3 are shown together in Table 1 below.

Clinical Experiment Item Before treatment After treatment One N Example 1 76 76 Comparative Example 1 75 75 RBC (10 "/ L) Example 1 4.53 ± 0.45 4.63 ± 0.43 Comparative Example 1 4.51 ± 0.44 4.53 ± 1.20 Hb (g / L) Example 1 139.3 ± 1.48 142.9 ± 12.9 Comparative Example 1 138.1 ± 0.90 139.0 ± 3.32 2 N Example 1 46 46 Comparative Example 1 45 45 RBC (10 "/ L) Example 1 4.44 ± 0.45 4.59 ± 0.45 Comparative Example 1 4.42 ± 0.33 4.43 ± 0.81 Hb (g / L) Example 1 138.6 ± 1.54 143.7 ± 12.2 Comparative Example 1 138.3 ± 0.90 141.5 ± 4.25 3 N Example 1 30 30 Comparative Example 1 30 30 RBC (10 "/ L) Example 1 4.67 ± 0.41 4.70 ± 0.40 Comparative Example 1 4.50 ± 0.38 4.52 ± 0.66 Hb (g / L) Example 1 140.3 ± 14.0 141.5 ± 14.2 Comparative Example 1 140.0 ± 10.0 141.1 ± 0.87

In Table 1, red blood cells and hemoglobin before and after the treatment of Example 1, although the increase is not obvious, there is no obvious effect on the quantitation of red blood cells and hemoglobin.

The measurement results before and after the treatment of serum Ca ²⁺ , P ⁼ of clinical trials 1 to 3 are shown in Table 2 below.

Clinical Experiment Item Before treatment After treatment One N Example 1 76 76 Comparative Example 1 76 76 Ca ²⁺ (mmol / L) Example 1 2.31 ± 0.13 2.34 ± 0.12 Comparative Example 1 2.30 ± 0.11 2.31 ± 1.38 P ⁼ (mmol / L) Example 1 1.13 ± 0.36 1.20 ± 0.35 Comparative Example 1 1.12 ± 0.67 1.18 ± 0.52 2 N Example 1 46 46 Comparative Example 1 43 43 Ca ²⁺ (mmol / L) Example 1 2.33 ± 0.14 2.37 ± 0.12 Comparative Example 1 2.32 ± 0.55 2.34 ± 0.08 P ⁼ (mmol / L) Example 1 1.16 ± 0.19 1.27 ± 0.13 Comparative Example 1 1.12 ± 0.18 1.15 ± 0.22 3 N Example 1 30 30 Comparative Example 1 29 29 Ca ²⁺ (mmol / L) Example 1 2.27 ± 0.11 2.28 ± 0.11 Comparative Example 1 2.27 ± 0.12 2.27 ± 0.07 P ⁼ (mmol / L) Example 1 1.08 ± 0.52 1.09 ± 0.53 Comparative Example 1 1.07 ± 0.50 1.07 ± 0.51

In Table 2, since the levels of serum Ca ²⁺ and P ⁼ after the treatment of Example 1 were raised to a certain level, it can be seen that the statistical significance is significant.

The measurement results before and after the treatment of vitamin D3 contained in the serum of Clinical Experiments 1 and 2 are shown in Table 3 below. Units for values are μg / ml, X ± SD.

Clinical Experiment Item Before treatment After treatment One N Example 1 53 53 Comparative Example 1 52 52 Vitamin D ₃ (µg / ml) Example 1 0.77 ± 0.31 2.31 ± 1.12 Comparative Example 1 0.75 ± 1.01 0.77 ± 1.10 2 N Example 1 53 53 Comparative Example 1 52 52 Vitamin D ₃ (µg / ml) Example 1 0.77 ± 0.31 2.31 ± 1.12 Comparative Example 1 0.77 ± 0.32 1.88 ± 1.45

After treatment, the vitamin D ₃ content in serum was markedly elevated and statistically significant. It can be seen that this treatment affects the vitamin D ₃ content in serum.

The measurement results before and after the treatment of bone density in the radial and ulna of clinical trials 1 and 3 are shown in Table 4 below. Units for values are g / cm 2, X ± SD.

Clinical Experiment Item Before treatment After treatment One N Example 1 30 30 Comparative Example 1 29 29 Radius (g / cm) Example 1 0.895 ± 0.232 0.927 ± 0.215 Comparative Example 1 0.895 ± 0.222 0.911 ± 0.198 Ulna (g / cm) Example 1 0.774 ± 0.221 0.776 ± 0.224 Comparative Example 1 0.771 ± 0.234 0.772 ± 0.243 3 N Example 1 30 30 Comparative Example 1 30 30 Radius (g / cm) Example 1 0.895 ± 0.232 0.927 ± 0.215 Comparative Example 1 0.895 ± 0.231 0.918 ± 0.177 Ulna (g / cm) Example 1 0.774 ± 0.221 0.776 ± 0.224 Comparative Example 1 0.775 ± 0.250 0.775 ± 0.223

In Table 4, the radial bone density after the treatment of Example 1 was significantly higher and statistically significant. It can be seen that this treatment has a constant effect on BMD, but the ulnar BMD is not significant and statistically insignificant.

In the present invention as described above, the wavelength of 280-320nm is generated stably, and the light intensity of the medium-ultraviolet ultraviolet ray is strengthened, thereby increasing the production and conversion of vitamin D ₃ when subjected to the skin. Even if the patient is active in daylight, the patient does not feel uncomfortable for a long time and there are no side effects such as skin pigmentation or conjunctival hyperemia. Therefore, as well as the treatment of rickets, it is effective in the treatment or prevention of osteoporosis. In addition, the heat stability of daylighting is improved, and the deposition in the lamp tube is easy. In terms of raw materials, it is made of relatively inexpensive materials, so there is an economic effect. Since it performs the function of an artificial sun, lighting is also a good match.

Claims (2)

Equivalent to 80% to 95% by weight of Ca ₃ (PO ₄ ) ₂ (calcium phosphate), which is a fluorescence, SrCO ₃ (strotium carbonate), MgO (magnesium oxide), H ₃ BO ₃ (hydrogen borate), PbO ₂ (oxidation) Lead) and CeO ₂ (cerium oxide) and Gd ₂ O ₃ (gadolinium oxide) as a activator mixed powder of high temperature firing, the isotube is a medium-wave ultraviolet light for osteoporosis therapy characterized in that it is composed of sodium-based glass . 80 to 95% by weight of Ca ₃ (PO ₄ ) ₂ (calcium phosphate) as a fluorescent substance, 3 to 18% by weight of SrCO ₃ (stromium carbonate), 0.05 to 15.05% by weight of MgO (magnesium oxide), H ₃ BO ₃ (hydrogen borate ) 1 to 16%, PbO ₂ (lead oxide) 0.4 to 15.4%, and CeO ₂ (cerium oxide) 0.30 to 15.30% by weight and Gd ₂ O ₃ (gadolinium oxide) 0.25 to 15.25% by weight as an active agent Equivalent composition, such as medium-wave ultraviolet-rays for osteoporosis therapy.